MedCity News July 18, 2024
The Federal Trade Commission recently released an interim report that details how the practices of pharmacy benefit managers negatively impact patients and pharmacies. Some experts hope for legislative action based on the report.
About two years after launching an investigation into pharmacy benefit managers, the Federal Trade Commission has finally released some of its findings — and they don’t bode well for the prescription drug middlemen.
Last week’s interim report explains how concentrated the PBM market has become, allowing the companies to generate outsize profits while patients and independent pharmacies struggle. The six largest PBMs — CVS Caremark, Express Scripts, Optum Rx, Humana Pharmacy Solutions, MedImpact and Prime Therapeutics — manage nearly 95% of all prescriptions filled in the U.S.
...Today's Sponsors
Today's Sponsor